A multi-center, prospective, observational-cohort controlled study of clinical outcomes following COVID-19 convalescent plasma therapy in hospitalized COVID-19 patients
Clinical Infectious Diseases — Chauhan L, Pattee J, Ford J, et al. | September 23, 2021
No significant improvement in patient hospitalization length of stay or inpatient mortality was conferred by treatment with COVID19 convalescent plasma (CCP) in hospitalized COVID19 patients.
This prospective, observational multicenter trial included hospitalized COVID19 patients treated with CCP and those not treated with CCP.
Overall 468 hospitalized COVID19 cases were entered into propensity score matching with 188 patients matched for assessment in the CCP-treatment and control arms.
CCP-treated patients were found to have increased length of hospital stay and no change in inpatient mortality relative to controls.
Subgroup study of CCP-administered patients within 7 days of admission revealed no difference in length of hospitalization and inpatient mortality.